Delivery Order SPE2DB22D2007-SPE2DB25FJ1MT
Award Date
5/14/25
Potential Completion Date
5/15/25
Potential Value
$8.9K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order valued at $153,284 for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 4, 2023. The contract is a firm fixed-price arrangement, and there is no set-aside designation indicated. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award is for the delivery of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML to the Defense Logistics Agency (DLA). The contract, valued at $1,971.60, was awarded to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract is a Firm Fixed Price Delivery Order with a completion date of July 24, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation, to provide the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The $3,943.20 award has a completion date of February 6, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as a prime contractor to DLA Troop Support Medical, supplying pharmaceuticals and medical supplies in...
The U.S. Defense Logistics Agency (DLA) has awarded a Delivery Order contract worth $2,365.92 to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This Delivery Order is issued under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. The IDC enables DLA to efficiently procure essential...
The federal contract award is for the delivery of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award, valued at $52,789.50, is a Firm Fixed Price delivery order with a completion date of June 16, 2022. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $16,849.60 and is a Firm Fixed Price Delivery Order, awarded to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of May 14, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp...
This federal contract award is for the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,361.62 fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of November 13, 2024. The contract is not designated with any set-aside requirements, indicating open competition. AmerisourceBergen holds a $999,999,999...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $7,886.40 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of February 12, 2024. This delivery order is part of an indefinite delivery contract (IDC) valued at up to $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary vehicle for the...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The order has a completion date of February 8, 2024 and a potential value of $1,577.28. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is not associated with any set-aside designation. Additionally, Amerisourcebergen Drug Corp holds...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a ceiling value of $7,664.20 and an ultimate completion date of November 15, 2023. This is a firm fixed-price delivery order contract, and there is no set-aside designation. Amerisourcebergen Drug Corp holds a significant...